Nutrition and gut metabolites in heart surgery patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study will collect preoperative blood and intraoperative cardiac tissue to map gut microbiota-derived metabolites using targeted and untargeted mass spectrometry. A subset of participants will be randomized to receive postoperative probiotic supplementation or placebo, with serial blood draws to track metabolomic and microbiome changes. The design links tissue-level and circulating metabolite measurements with a nutritional intervention to probe the gut–heart metabolic axis. Clinical outcomes and metabolic profiles will be compared between the probiotic and placebo groups over follow-up.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Scheduled to undergo cardiovascular surgery
* Completed preoperative clinical and imaging evaluations
* Willing to provide informed consent
* Willing to receive potential probiotic supplementation

Exclusion Criteria:

* Use of antibiotics, probiotics, or other treatments affecting gut microbiota within 4 weeks
* History of major gastrointestinal disease

Where it's running

• Fu Jen Catholic University Hospital, Fu Jen Catholic University
  New Taipei City, Taiwan Recruiting

Study contacts

• Principal investigator: Ke-Yun Chao, PhD — Fu Jen Catholic University
• Study coordinator: Ke-Yun Chao, PhD
• Email: C00152@mail.fjuh.fju.edu.tw
• Phone: +886-905-301-879

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cardio-Metabolic Clinic care for adults with type 2 diabetes and cardiovascular disease

  This trial tests whether a specialized Cardio-Metabolic Clinic can improve heart function and overall health for adults with type 2 diabetes and cardiovascular disease compared with usual care.

  Recruiting Odense University Hospital · Svendborg · NCT07878325

• Petrelintide for weight loss in people with overweight/obesity and heart disease

  This study tests whether petrelintide helps people with overweight or obesity and cardiovascular disease lose weight when added to a reduced-calorie diet and more physical activity, compared with a placebo.

  Recruiting at 3 sites Phase 3 Hoffmann-La Roche · Anniston, Alabama and 2 other locations · NCT07843472

• VERVE-102 for adults with or at high risk for heart disease

  This study tests whether VERVE-102 can lower bad cholesterol (LDL-C) compared with a placebo in adults with plaque buildup or high risk for it.

  Recruiting Phase 2 Verve Therapeutics, Inc. · DeSoto, Texas · NCT07839936

• Biomarkers to predict CSA-AKI risk before heart surgery

  This study tests new biomarkers to see if they can predict CSA-AKI risk in adults undergoing cardiovascular surgery.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07811570

• Clazakizumab for adults with high hsCRP at risk for a heart event

  This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.

  Recruiting at 32 sites Phase 2 Eli Lilly and Company · Huntsville, Alabama and 45 other locations · NCT07783802

• Improving Care for underserved older Black patients with cardiovascular and other chronic conditions

  This study tests a culturally tailored approach to patient-centered care for older African American patients with cardiovascular disease and other conditions who receive care at a community hospital.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama · NCT07748858

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.